Your browser doesn't support javascript.
loading
Integrative analyses reveal prognostic and immunogenic characteristics of m7G methylation regulators in patients with glioma.
Tang, Lingwei; Li, Yanyan; Shen, Lin; Li, Na; Shen, Liangfang; Li, Zhanzhan.
Afiliación
  • Tang L; Department of Oncology, Xiangya Hospital, Central South University Changsha 410008, Hunan, P. R. China.
  • Li Y; Department of Nursing, Xiangya Hospital, Central South University Changsha 410008, Hunan, P. R. China.
  • Shen L; Department of Oncology, Xiangya Hospital, Central South University Changsha 410008, Hunan, P. R. China.
  • Li N; Department of Oncology, Xiangya Hospital, Central South University Changsha 410008, Hunan, P. R. China.
  • Shen L; Department of Oncology, Xiangya Hospital, Central South University Changsha 410008, Hunan, P. R. China.
  • Li Z; Department of Oncology, Xiangya Hospital, Central South University Changsha 410008, Hunan, P. R. China.
Am J Transl Res ; 15(1): 288-309, 2023.
Article en En | MEDLINE | ID: mdl-36777864
ABSTRACT

OBJECTIVES:

The expression profiles, biological mechanisms, and clinical relevance of m7G regulators in glioma were studied in this research.

METHODS:

Based on the Chinese Glioma Genome Atlas (CGGA) and The Cancer Genome Atlas (TCGA) datasets, glioma patients, can be categorized into three groups according to 29 m7G regulators, and different subtypes of glioma show different immune cell infiltration characteristics, function enrichment, and clinical prognosis. Three gene clusters were confirmed by utilizing the differentially expressed genes (DEGs) across the three m7G clusters.

RESULTS:

A prognostic signature based on 12 m7G regulators was established and validated, producing an effective tool for predicting overall survival (OS) in glioma patients. High m7G scores indicated elevated tumor mutation burden and activation of immunity, suggesting an inflamed tumor microenvironment phenotype with poor overall survival. Low m7G scores characterized by a lack of immune infiltration and low mutation burden indicated a non-inflamed phenotype with a favorable clinical prognosis. It was also found that the m7G risk scores can affect chemotherapy sensitivity and prognosis of patients who received immunotherapy. The hub gene EIF4E1B of m7G regulators can inhibit the in vitro progression of glioma cells by regulating PD-L1 expression through p53 signaling pathway-related inactivation.

CONCLUSIONS:

The m7G prognostic signature can be a biomarker of the overall survival of patients with glioma. An initial in-vitro experiment suggested the potential biological mechanisms of immune regulation, with m7G regulators affecting glioma progression by modulating immune responses. The present research provides a better understanding of how m7G regulators function in glioma progression as well as the impact on clinical outcomes, which can provide new insights that might be beneficial for precision therapy of glioma.
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Am J Transl Res Año: 2023 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Am J Transl Res Año: 2023 Tipo del documento: Article
...